Defining targets of protective immunity to vivax malaria using human monoclonal antibodies

Document text

Principal Investigator: Christopher L King
Organization: CASE WESTERN RESERVE UNIVERSITY
Fiscal Year: 2024
Award: $697,088
Funding agency: National Institute of Allergy and Infectious Diseases

The goal of our proposal is to develop new approaches for the prevention and treatment of human malaria
caused by the parasite Plasmodium vivax (P. vivax). This type of malaria, known as vivax malaria, is the most
widely distributed type of malaria with 3.3 billion people at risk and at least 15 million clinical cases worldwide
each year. As the most common form of malaria outside sub-Saharan Africa, it can cause severe illness and
death across a large segment of the world's population. Most individuals exposed to P. vivax through repeated
infection gain partial immunity over time. The immunity is mediated, in part, by acquired antibodies (Abs) to
essential parasite proteins that can block the parasite invasion into liver and red blood cells thereby preventing
infection and if infected reduce the risk of disease. This proposal aims to isolate human monoclonal antibodies
(mAbs) from individuals with immunity to vivax malaria that recognize a few key molecules known to be
essential for invasion of liver and red blood cells. Once isolated these mAbs will be evaluated as to whether
they block parasite invasion of liver and red cells in vitro, and in vivo using murine models and genetically
modified parasites. Monoclonal Abs with potent blocking activity will be further characterized as to exactly how
and where they interact with parasite proteins and whether individuals in diverse populations also have the
same or similar antibodies. This information can be used to help to design a vaccine against vivax malaria.
These mAbs can also be used for treatment of severely ill patients, or for prevention of vivax malaria over time,
since a single injection of modified mAbs can last for weeks and even months.

Terms: <0-11 years old><21+ years old><7S Gamma Globulin><Address><Adjuvant><Adult><Adult Human><Affinity><Africa South of the Sahara><Antibodies><Antigenic Determinants><Antigens><Antisera><Approaches to prevention><Area><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Beds><Binding Determinants><Binding Proteins><Bioassay><Biological Assay><Biomass><Blood><Blood Reticuloendothelial System><Blood erythrocyte><Blood reticulocyte><Brazil><Cambodia><Cell Body><Cells><Cessation of life><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chronic Disease><Chronic Illness><Clinical><Clinical Treatment Moab><Clone Cells><Complement><Complement Proteins><Copy Number Polymorphism><Data><Death><Development><Diffusely basophilic erythrocyte><Drug resistance><East New Guinea><Epitopes><Erythrocytes><Erythrocytic><Ethiopia><Event><Exposure to><Fever><Fixation><Fusion Protein><Gene Copy Number><Gene Dosage><Gene Modified><Genetic Polymorphism><Geography><Goals><Groups at risk><Health Policy><Hepatic><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocyte><Hu-mABs><Human><IgG><Immune><Immune Sera><Immunes><Immunity><Immunize><Immunoglobulin G><Immunologist><In Vitro><Individual><Infection><Infection prevention><Injections><Invaded><Kampuchea><Khmer Republic><Knowledge><Ligand Binding Protein><Ligand Binding Protein Gene><Liver><Liver Cells><Long-term cohort><Longitudinal cohort><Longterm cohort><Lymphatic cell><Lymphocyte><Lymphocytic><Malaria><Malaria Vaccines><Malarial Vaccines><Marrow erythrocyte><Marrow reticulocyte><Measures><Mediating><Modern Man><Monoclonal Antibodies><Morbidity><Morbidity - disease rate><P falciparum><P vivax><P vivax vaccine><P. falciparum><P. vivax><P. vivax vaccine><P.falciparum><Paludism><Papua New Guinea><Parasites><Patients><People at risk><Persons at risk><Plasmodium Infections><Plasmodium falciparum><Plasmodium vivax><Plasmodium vivax Malaria><Plasmodium vivax vaccine><Polychromatophilic Erythrocyte><Population><Population Heterogeneity><Populations at Risk><Prevent infection><Prevention><Prevention approach><Primary Infection><Production><Protein Binding><Proteins><Public Health><Pyrexia><Receptor Protein><Recommendation><Red Blood Cells><Red Cell><Relapse><Residual><Residual state><Reticulocytes><Risk><Risk Reduction><Role><Solomon Islands><Sporozoites><Sub-Saharan Africa><Subsaharan Africa><Syndrome><Technology><Time><Transcend><Transgenic Organisms><Transmission><Vaccines><Vivax Malaria><Work><adulthood><apical membrane><blood corpuscles><bound protein><chronic disorder><circumsporozoite protein><complementation><copy number variant><copy number variation><cs protein><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><disease risk><disorder risk><diverse populations><drug resistant><experiment><experimental research><experimental study><experiments><febrile><febris><gene modification><genetically modified><health care policy><healthcare policy><hepatic body system><hepatic organ system><heterogeneous population><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immune serum><immunogen><in vitro Assay><in vivo><innovate><innovation><innovative><kids><lymph cell><mAbs><migration><monoclonal Abs><mortality><mouse model><murine model><neutralizing mAb><neutralizing monoclonal antibodies><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><new vaccines><next generation><next generation therapeutics><next generation vaccines><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><novel vaccines><parasite invasion><polymorphism><population diversity><prevent><preventing><rational design><receptor><receptor binding><receptor bound><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><resistance to Drug><resistant to Drug><risk-reducing><sample fixation><social role><structural determinants><structural factors><transgenic><transmission process><vaccine development><vaccine strategy><vaccines against malaria><youngster>